An Automated Tool for Finding Cancer-Fighting Peptide Targets | Research

The takeaway

ProTECT is an automated pipeline that identifies cancer-specific peptide neoepitopes from patient sequencing data, processing samples in under 30 minutes.

<30 min
Per sample processing time for identifying cancer neoepitope peptides from raw sequencing data

What the researchers found

ProTECT automates cancer neoepitope peptide identification from patient data, identifying recurrent neoepitopes from TMPRSS2-ERG fusions and SPOP mutations in prostate cancer.

Why it matters

Personalized cancer vaccines depend on identifying the right peptide targets. ProTECT makes this reproducible and scalable, potentially accelerating clinical adoption.

The numbers in context

326 samples; <30 min per sample; identified TMPRSS2-ERG and SPOP neoepitopes; free/open-source

How the study worked

Computational pipeline development with validation on 326 TCGA prostate adenocarcinoma samples. Includes alignment, HLA haplotyping, mutation calling, peptide:MHC prediction, and ranking.

Who was studied

TCGA Prostate Adenocarcinoma cohort (326 samples, computational analysis)

What this study cannot tell us

Computational predictions require experimental validation. Predicted neoepitopes may not be immunogenic in vivo.

How to read the evidence

Computational tool validated on a large dataset. Strong technical demonstration but predicted peptides require wet-lab confirmation.

When this study was published

Published in 2020. The neoepitope prediction field has continued to advance.

The bigger picture

As cancer immunotherapy becomes more personalized, tools that rapidly identify patient-specific peptide targets will be essential infrastructure for clinical implementation.

Questions still open

How does ProTECT's prediction accuracy compare to experimentally validated neoepitopes?
Can ProTECT be integrated into clinical workflows?
How well do predicted neoepitopes translate to actual T cell responses?

Common questions

What are cancer neoepitopes?

Neoepitopes are small peptide fragments created by mutations unique to a patient's tumor. Because they're not found in normal cells, the immune system can be trained to recognize and attack cells displaying these peptides.

Why is automating neoepitope prediction important?

Identifying the right peptide targets from tumor data previously required multiple separate tools and significant expertise. ProTECT streamlines this into a single automated pipeline, making personalized cancer immunotherapy more accessible.

Read the original research

ProTECT-Prediction of T-Cell Epitopes for Cancer Therapy.

Frontiers in immunology, 11, 483296

View on PubMed ↗Publisher’s paper ↗

Citation

Rao, Arjun A; Madejska, Ada A; Pfeil, Jacob; Paten, Benedict; Salama, Sofie R; Haussler, David. (2020). ProTECT-Prediction of T-Cell Epitopes for Cancer Therapy.. Frontiers in immunology, 11, 483296. https://doi.org/10.3389/fimmu.2020.483296